Bugajski J, Gadek-Michalska A, Ołowska A, Borycz J, Głód R
Department of Physiology, Polish Academy of Sciences, Cracow, Poland.
J Physiol Pharmacol. 1996 Dec;47(4):649-59.
Involvement of histamine receptors and hypothalamic and hippocampal histamine in stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by vasopressin (AVP) was investigated in conscious rats. The HPA activity was assessed by measuring serum corticosterone levels. One hour after administration AVP, (5 micrograms/kg) given i.p. significantly raised the serum corticosterone and hippocampal histamine levels, while the hypothalamic histamine content was not affected. Pretreatment with the inhibitor of the brain histamine synthesis alpha-fluoromethylhistidine (alpha-FMH) (50 mg/kg i.p.) considerably reduced both the AVP-elicited serum corticosterone response and the hypothalamic and hippocampal histamine levels. The histamine H1- and H2-receptor-antagonists mepyramine (0.01 mg/kg) and ranitidine (0.1 mg/kg), given ip 15 min prior to AVP, significantly impaired the AVP-induced rise in the serum corticosterone level and totally abolished the AVP-elicited increase in the histamine content in the hippocampus; moreover mepyramine significantly lowered this content in hypothalamus. Pretreatment with the histamine H3-receptor antagonist thioperamide (5 mg/kg i.p.) also significantly decreased the AVP-elicited corticosterone response, but did not alter the histamine content in either brain structure examined. These results indicate that central histamine H1-, H20 and H3-receptors significantly mediate the stimulatory action of AVP on the pituitary-adrenocortical axis. Hippocampal histamine may be involved in mediation of the AVP-induced effect via H1- and H2-receptors. The inhibitory effect of thioperamide seems to be located directly at non H3-intracellular sites of the pituitary-adrenocortical axis.
在清醒大鼠中研究了组胺受体以及下丘脑和海马组胺在血管加压素(AVP)刺激下丘脑-垂体-肾上腺(HPA)轴中的作用。通过测量血清皮质酮水平评估HPA活性。腹腔注射AVP(5微克/千克)1小时后,血清皮质酮和海马组胺水平显著升高,而下丘脑组胺含量未受影响。用脑组胺合成抑制剂α-氟甲基组氨酸(α-FMH)(50毫克/千克腹腔注射)预处理可显著降低AVP引起的血清皮质酮反应以及下丘脑和海马组胺水平。在AVP注射前15分钟腹腔注射组胺H1和H2受体拮抗剂美吡拉敏(0.01毫克/千克)和雷尼替丁(0.1毫克/千克),可显著削弱AVP诱导的血清皮质酮水平升高,并完全消除AVP引起的海马组胺含量增加;此外,美吡拉敏可显著降低下丘脑的组胺含量。用组胺H3受体拮抗剂硫代哌啶(5毫克/千克腹腔注射)预处理也可显著降低AVP引起的皮质酮反应,但未改变所检测的两个脑区的组胺含量。这些结果表明,中枢组胺H1、H2和H3受体显著介导AVP对垂体-肾上腺皮质轴的刺激作用。海马组胺可能通过H1和H2受体参与介导AVP诱导的效应。硫代哌啶的抑制作用似乎直接位于垂体-肾上腺皮质轴的非H3细胞内位点。